{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+B", "query": { "intervention": "Formulation B" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 517, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+B&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T07:13:04.385Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01443650", "title": "Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "alirocumab SAR236553 (REGN727)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2011-07", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443650" }, { "nct_id": "NCT02083640", "title": "Relative Bioavailability For Palbociclib Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Palbociclib Formulation Reference", "type": "DRUG" }, { "name": "Palbociclib Formulation Test", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2014-03", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02083640" }, { "nct_id": "NCT03495921", "title": "A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ewing Sarcoma", "Ewing Family of Tumors", "Ewing's Tumor Metastatic", "Ewing's Sarcoma Metastatic", "Ewing's Tumor Recurrent", "Rare Diseases", "Sarcoma", "Neoplasms, Connective and Soft Tissue", "Neoplasms by Histologic Type", "Neoplasms, Bone Tissue", "Neoplasms, Connective Tissue", "Sarcoma, Ewing", "Neoplasms" ], "interventions": [ { "name": "Vigil", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 32, "start_date": "2018-08-21", "completion_date": "2022-01-20", "has_results": true, "last_update_posted_date": "2023-04-26", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 15, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03495921" }, { "nct_id": "NCT02270944", "title": "Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Streptococcal", "Streptococcal Infections" ], "interventions": [ { "name": "GBS Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 1053, "start_date": "2014-11-20", "completion_date": "2015-09-22", "has_results": true, "last_update_posted_date": "2019-12-05", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 5, "location_summary": "Redding, California • Lenexa, Kansas • Baltimore, Maryland + 2 more", "locations": [ { "city": "Redding", "state": "California" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Stevensville", "state": "Michigan" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270944" }, { "nct_id": "NCT03107871", "title": "Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cmv Congenital", "CMV", "Congenital Cmv", "SNHL", "Sensorineural Hearing Loss" ], "interventions": [ { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Simple Syrup", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albert Park", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "12 Months", "sex": "ALL", "summary": "1 Month to 12 Months" }, "enrollment_count": 10, "start_date": "2018-08-31", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 30, "location_summary": "Palo Alto, California • San Diego, California • San Francisco, California + 25 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107871" }, { "nct_id": "NCT01272180", "title": "Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Meningococcal Disease" ], "interventions": [ { "name": "Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.", "type": "BIOLOGICAL" }, { "name": "Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.", "type": "BIOLOGICAL" }, { "name": "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.", "type": "BIOLOGICAL" }, { "name": "Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "10 Years to 25 Years" }, "enrollment_count": 484, "start_date": "2011-08", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Madera, California • Paramount, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Madera", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "Bardstown", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272180" }, { "nct_id": "NCT05283681", "title": "A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 226, "start_date": "2019-04-02", "completion_date": "2019-11-11", "has_results": false, "last_update_posted_date": "2022-03-17", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 2, "location_summary": "Grayslake, Illinois • Austin, Texas", "locations": [ { "city": "Grayslake", "state": "Illinois" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283681" }, { "nct_id": "NCT06742086", "title": "A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 72, "start_date": "2024-12-19", "completion_date": "2025-10-08", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 2, "location_summary": "Grayslake, Illinois • Austin, Texas", "locations": [ { "city": "Grayslake", "state": "Illinois" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742086" }, { "nct_id": "NCT06733675", "title": "Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "Pharmacokinetics", "Safety", "Drug-Drug Interaction (DDI)", "FDC" ], "interventions": [ { "name": "Ledaborbactam etzadroxil", "type": "DRUG" }, { "name": "Ceftibuten", "type": "DRUG" }, { "name": "Ceftibuten-ledaborbactam etzadroxil", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "amoxicillin-clavulanate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 96, "start_date": "2025-01-07", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06733675" }, { "nct_id": "NCT07748351", "title": "A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MK-4082 Formulation 1 (F1)", "type": "DRUG" }, { "name": "MK-4082 Formulation 2 (F2)", "type": "DRUG" }, { "name": "MK-4082 Formulation 4 (F4)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 48, "start_date": "2026-08-25", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-03T07:13:04.385Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07748351" } ] }